Video / CNNA new cancer drug has shocked researchers with how well it has performed in a breakthrough study, which virtually cured every trial participant. Dostarlimab, a monoclonal antibody drug that is approved to treat endometrial cancer in the UK, exceeded expectations in a trial held at New York's Memorial Sloan Kettering Cancer Centre. It is given to around 100 advanced endometrial cancer patients every year, aiming to improve patients' quality of life and avoid chemotherapy. "No matter what stage the cancer is, we have a trial at Memorial Sloan Kettering that may help you. Paper co-author Dr Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Centre, said "there were a lot of happy tears".

Source: New Zealand Herald June 08, 2022 09:21 UTC